Physician profile
Arthur D Klein
NPI 1568486793
$25,014.71
in general payments reported to CMS, 2019-2025
28 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,053 · 2020: $4,198 · 2021: $4,623 · 2022: $11K · 2023: $2,024 · 2024: $1,251 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,861 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,860.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $487.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14,114.99 | 2021-2025 | |
| Allergan, INC. | $3,893.73 | 2020-2021 | |
| Novo Nordisk INC | $1,453.63 | 2019-2025 | Rybelsus, Ozempic, Saxenda |
| Astrazeneca Pharmaceuticals LP | $1,143.62 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $993.80 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $803.30 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $432.86 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $337.74 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.89 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $256.23 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $255.79 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $174.33 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $146.33 | 2025 | |
| Astellas Pharma US INC | $131.84 | 2019-2023 | Veozah |
| Abbott Laboratories | $119.13 | 2022-2024 | Freestyle Libre |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $60.58 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $57.91 | 2020-2024 | Gardasil, Gardasil 9, Capvaxive |
| Phathom Pharmaceuticals, INC. | $51.13 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $50.88 | 2019-2020 | |
| Exact Sciences Corporation | $43.00 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $42.18 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $33.12 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.74 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.99 | 2022 | |
| Avanir Pharmaceuticals, INC. | $23.77 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.03 | 2021 | |
| Currax Pharmaceuticals LLC | $17.52 | 2025 | Contrave |
| Amgen INC. | $14.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.